for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beam Therapeutics Inc

BEAM.N

Latest Trade

95.95USD

Change

0.73(+0.77%)

Volume

4,833

Today's Range

95.95

 - 

98.07

52 Week Range

22.15

 - 

138.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
95.22
Open
98.07
Volume
4,833
3M AVG Volume
17.74
Today's High
98.07
Today's Low
95.95
52 Week High
138.05
52 Week Low
22.15
Shares Out (MIL)
66.35
Market Cap (MIL)
6,323.88
Forward P/E
-15.25
Dividend (Yield %)
--

Next Event

Q3 2021 Beam Therapeutics Inc Earnings Release

Latest Developments

More

Beam Therapeutics Provides Business And Pipeline Updates And Reports Second Quarter 2021 Financial Results

Beam Therapeutics Says Co & Jefferies Entered Into Amendment To Sales Agreement

Apellis & Beam Therapeutics Enter Research Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beam Therapeutics Inc

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS). The Company has three development candidates, such as BEAM-101, BEAM-102 and BEAM-201 in which two candidates targeting hemoglobinopathies and one candidate in T-cell therapy program.

Industry

Biotechnology & Drugs

Contact Info

26 Landsdowne St

CAMBRIDGE, MA

02139-4216

United States

+1.857.3278775

https://beamtx.com/

Executive Leadership

Giuseppe Ciaramella

President, Chief Scientific Officer

John M. Evans

Chief Executive Officer, Director

Terry-Ann Burrell

Chief Financial Officer, Treasurer

Kristina M. Burow

Independent Director

Graham K. Cooper

Independent Director

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-14.050

2020

-4.190

2021(E)

-6.251
Price To Earnings (TTM)
--
Price To Sales (TTM)
263,495.20
Price To Book (MRQ)
11.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.16
LT Debt To Equity (MRQ)
0.76
Return on Investment (TTM)
-79.53
Return on Equity (TTM)
-68.35

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up